Topic summary

[2026 update] US compounding rules and how they changed

Regional › North America FDA compounding insurance Solved

This is a generated summary. It shows the 5 most-liked posts from a topic of 38, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

a.hartmannTL28 Mar 2025 · edited#3

The opening post and I disagree about the size of the effect, not about the direction.

The denial letter is the specification for the appeal. It states a criterion and the job is to demonstrate that criterion in the letter's own language.

28 likes 17mo

k.haddadTL2 Solution24 Mar 2025#5

Anyone reporting an outcome should give the stated reason rather than the verdict. The reason is the part somebody else can use.

I looked this up rather than remembered it, which is the right order.

7 likes 16mo

l.aaltonenTL3Regular2 May 2025#11

t.nardone, post #10: Post #7 is right about the mechanism and I think understates the practical bit. Where a manufacturer runs a direct supply route, that is a commercial arrangement rather than a regulatory change, and it can end. Go to post

The public assessment documents published at approval are free, detailed and largely unread here.

27 likes in reply to #10 15mo

s.demirTL220 Jun 2025 · edited#20

b.nwosu, post #18: Where a compounding pathway existed and closed, posts describing it stay in the archive and should be read with their date attached. Go to post

On post #16 — agreed on the reasoning, with one qualification.

Compounded preparations and authorised products are different regulatory categories with different oversight, and conflating them produces most of the confusion here.

If anyone can point at the primary source I would be grateful.

29 likes in reply to #18 13mo

c.castellanosTL213 Aug 2025#31

Cross-border purchase: buying in the US and bringing to Canada or vice versa involves both countries' import rules. The medication is legal but crossing borders with it is regulated.

33 likes 11mo

Read the full topic (38 posts)

This topic was referenced in

US compounding rules and how they changedRegional › North America · 68 replies
Telehealth prescribing models in the USRegional › North America · 102 replies
Follow-up: State-level differences that actually matterRegional › North America · 96 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
US compounding rules and how they changed Regional › North America FDA telehealth insurance Closed US compounding rules and how they changed — setting out what I have, and where I think it stops being reliable. Reporting a regional experience with the date and the jurisdiction attached, because an undated…	+62	68	1.4k	20mo
Coverage in the US: a map of the usual obstacles Regional › North America FDA insurance telehealth compounding Coverage in the US: a map of the usual obstacles — setting out what I have, and where I think it stops being reliable. Trying to establish the boundary conditions on coverage. The general claim is fine; I…	+46	50	7.9k	5mo
Second pass at: Coverage in the US: a map of the usual obstacles Regional › North America insurance telehealth compounding FDA On the subject in the title: Second pass at: Coverage in the US: a map of the usual obstacles Working notes rather than a conclusion. Two things I would like separated before anyone answers on Coverage,…		4	62k	9mo
State-level differences that actually matter Regional › North America compounding telehealth insurance FDA Solved On the subject in the title: State-level differences that actually matter Working notes rather than a conclusion. The question about state-level differences that I actually want answered is the second one…	+6	10	56k	10mo
Canadian access and provincial variation Regional › North America compounding telehealth FDA insurance Posting this under the heading it deserves: Canadian access and provincial variation Everything below is what sits behind that. Trying to establish the boundary conditions on canadian access and provincial…	+74	80	7.7k	18mo

Related topics — sharing the tags FDA, compounding, insurance

Topic	Participants	Replies	Views	Activity
Substitution between formats during a shortage — what changed since Access › Shortages shortage formulary FDA compounding Solved Substitution between formats during a shortage — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of Substitution between formats…	+17	21	2.7k	9d
Coming back to: Official shortage notices and what they authorise Access › Shortages FDA compounding shortage formulary Official shortage notices and what they authorise Writing it up because I had to work it out twice and would rather nobody else did. Official shortage notices — I have the observation and I do not trust my…	+85	92	5.5k	11mo
Official shortage notices and what they authorise Access › Shortages compounding formulary shortage Posting this under the heading it deserves: Official shortage notices and what they authorise Everything below is what sits behind that. Trying to work out what would count as evidence on official shortage…	+106	119	18k	1mo
Cost per milligram, computed honestly across formats — a second dataset Access › Pricing cost per milligram formulary compounding Closed Cost per milligram, computed honestly across formats — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because…		2	27k	13mo
Enforcement priorities versus written rules Sourcing › Regulatory FDA personal import MHRA Enforcement priorities versus written rules — setting out what I have, and where I think it stops being reliable. Asking what a regulator's document actually says, since the summaries of it disagree. I have…		2	62k	15mo